Delving into the Latest Updates on Opebacan with Synapse

Overview

Basic Info

Drug Type

Recombinant protein

Synonyms

Neuprex, Opebacan (USAN/INN), Recombinant bactericidal permeability increasing protein 21

+ [2]

Target-

Action

inhibitors, enhancers

Mechanism

Angiogenesis inhibitors, Cell membrane permeability enhancers

Therapeutic Areas

Infectious DiseasesImmune System DiseasesOther Diseases

Active Indication-

Inactive Indication

Graft vs Host DiseaseInfectious DiseasesMeningococcal Infections+ [3]

Originator Organization

XOMA Royalty Corp.

Active Organization-

Inactive Organization

XOMA Royalty Corp.XOMA (US) LLC

The University of Texas Southwestern Medical Center

License Organization-

Drug Highest PhaseDiscontinuedPhase 3

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Sequence Code 524440693

Source: *****

The objectives of this study are as follows:
To demonstrate the safety of escalating doses of opebacan in subjects undergoing myeloablative allogeneic Hematopoietic Stem Cell Transplantation
To determine the pharmacokinetics of opebacan in subjects undergoing myeloablative allogeneic Hematopoietic Stem Cell Transplantation
To determine if IV administration of opebacan is associated with changes in biological markers for inflammation
To develop preliminary descriptive data on the occurrence and severity of Hematopoietic Stem Cell Transplantation related complications, including aGvHD

Start Date01 Feb 2007

Sponsor / Collaborator

XOMA (US) LLC

NCT00462904

/ TerminatedPhase 2IIT

Phase IIa Trial to Evaluate the Pharmacokinetic Response to Bactericidal/Permeability-increasing Protein (rBPI21) for the Treatment of Patients With Burn Injury.

The purpose of this study is to evaluate the safety of a protein called BPI that is naturally made by the body's white blood cells to fight infection.

Start Date01 Apr 2006

Sponsor / Collaborator

The University of Texas Southwestern Medical Center

100 Clinical Results associated with Opebacan

Login to view more data

100 Translational Medicine associated with Opebacan

Login to view more data

100 Patents (Medical) associated with Opebacan

Login to view more data

56

Literatures (Medical) associated with Opebacan

01 Aug 2020·Molecular TherapyQ1 · MEDICINE

Antibacterial Fusion Protein BPI21/LL-37 Modification Enhances the Therapeutic Efficacy of hUC-MSCs in Sepsis

Q1 · MEDICINE

Article

Author: Jiang, Dongpo ; Li, Zhan ; Wu, Xiaofeng ; Guo, Wei ; Liang, Huaping ; Tan, Yan ; Ao, Luoquan ; Song, Yuqing ; Ao, Xiang ; He, Xiao ; Hu, Xueting ; Xing, Wei ; Yuan, Peisong ; Xu, Xiang

Sepsis, which is characterized by multiple organ dysfunctions as a result of an unbalanced host-inflammatory response to pathogens, is potentially a life-threatening condition and a major cause of death in the intensive care units (ICUs). However, effective treatment or intervention to prevent sepsis-associated lethality is still lacking. Human umbilical cord mesenchymal stem cell (hUC-MSC) transplantation has been shown to have potent immunomodulatory properties and improve tissue repair yet lacks direct antibacterial and endotoxin clearance activities. In this study, we engineered hUC-MSCs to express a broad-spectrum antibacterial fusion peptide containing BPI21 and LL-37 (named BPI21/LL-37) and confirmed that the BPI21/LL-37 modification did not affect the stemness and immunoregulatory capacities of hUC-MSCs but remarkably, enhanced its antibacterial and toxin-neutralizing activities in vitro. Furthermore, we showed that administration of BPI21/LL-37-engineered hUC-MSCs significantly reduces serum levels of tumor necrosis factor α (TNF-α), interleukin 1β (IL-1β), and IL-6, whereas increases that of IL-10 in cecal ligation and puncture (CLP)-induced sepsis mouse model. Administration of BPI21/LL-37-engineered hUC-MSCs significantly reduced systemic endotoxin (lipopolysaccharide [LPS]) levels and organ bacterial load, ameliorated damage to multiple organs, and improved survival. Taken together, our study demonstrates that BPI21/LL-37-engineered hUC-MSCs might offer a novel therapeutic strategy to prevent or treat sepsis via enhanced antimicrobial and anti-inflammatory properties to preserve organ functions better.

07 Jun 2017·Annals of Agricultural and Environmental MedicineQ4 · MEDICINE

Utilisation of peptides against microbial infections – a review

Q4 · MEDICINE

ArticleOA

Author: Niemcewicz, Marcin ; Gryko, Romuald ; Michalski, Aleksander ; Mirski, Tomasz ; Bartoszcze, Michał

The emergence of resistance in microorganisms on a global scale has made it necessary to search for new antimicrobial factors. Antimicrobial peptides (AMPs) seem to meet these expectations. AMPs are produced by bacteria, viruses, plants, and animals, and may be considered as a new class of drugs intended for the prophylaxis and treatment of both systemic and topical infections. The aim of this study is to review the results of studies on the use of peptides to combat infections in vivo. Antimicrobial peptides may be applied topically and systemically. Among the peptides used topically, a very important area for their application is ophthalmology. AMPs in ophthalmology may be used mainly for the protection of contact lenses from ocular pathogens. Many AMPs are in clinical trials for application in the therapy of local infections. There may be mentioned such preparations as: pexiganan (magainin analogue), MX-226 (based on indolicidin), NEUPREX (isolated from human BPI (bactericidal/permeability-increasing) protein), IB-367 (variant of porcine protegrin), P113 (based on histatin), daptomycin, polymyxins, as well as peptidomimetics. In the combat against systemic infections are used such peptides as: P113D (modified P113 peptide containing D-amino acids), colistin, peptoids, and peptides containing non-typical amino acids or non-peptide elements. AMPs are also used as antiprotozoal, antifungal, antitoxic and immunostimulatory agents. The limitations in the use of peptides in the treatment of infections, such as susceptibility to proteolysis, and resistance of microorganisms to the peptides, are also discussed. AMPs are a promising strategy in the fight against microbial infections.

01 Apr 2014·Nanomedicine: Nanotechnology, Biology and MedicineQ2 · MEDICINE

Antimicrobial protein rBPI21-induced surface changes on Gram-negative and Gram-positive bacteria

Q2 · MEDICINE

Article

Author: Franquelim, Henri G ; Santos, Nuno C ; Carvalho, Filomena A ; Castanho, Miguel A R B ; Silva, Patrícia M ; Domingues, Marco M

New classes of antibiotics, such as antimicrobial peptides or proteins (AMPs), are crucial to deal with threatening bacterial diseases. rBPI21 is an AMP based on the human neutrophil BPI protein, with potential clinical use against meningitis. We studied the membrane perturbations promoted by rBPI21 on Gram-negative Escherichia coli and Gram-positive Staphylococcus aureus. Its interaction with bacteria was also studied in the presence of lipopolysaccharide (LPS), rBPI21 major ligand. Flow cytometry analysis of both bacteria shows that rBPI21 induces membrane depolarization. rBPI21 increases the negative surface charge of both bacteria toward positive values, as shown by zeta-potential measurements. This is followed by surface perturbations, culminating in cell lysis, as visualized by atomic force microscopy (AFM). Force spectroscopy measurements show that soluble LPS decreases the interaction of rBPI21 with bacteria, especially with S. aureus. This suggests that the rBPI21 LPS-binding pocket may also participate on the binding to Gram-positive bacteria.FROM THE CLINICAL EDITORIn this study, rBPI21, an antimicrobial protein based on the human neutrophil BPI protein, with potential clinical use against meningitis, is analyzed with multiple tools including zeta-potential measurements, clarifying its actions on E. coli and S. aureus. Since antimicrobial peptides are potentially important new additions to antibiotic regimens, studies like this represent important cornerstones in efficiency and mechanism of action testing of these new approaches.

1

News (Medical) associated with Opebacan

06 Sep 2006

·www.biospace.com

The Day In Review: EpiCept Corporation Drops On LidoPAIN Setback

September 6, 2006 – EpiCept lost almost one-third of its value after reporting that LidoPAIN, a sterile analgesic patch, did not diminish pain in a Phase III trial; the FDA advisory committee refused to recommend the cancer drug Genasense from Genta; Genzyme treated the first leukemia adult patient in a Phase III trial of Clolar; XOMA received orphan drug designation in Europe for Neuprex; SkyePharma out-licensed European rights for Flutiform, a therapy for asthma and COPD; Lexicon Genetics began a Phase I trial of a compound for cognitive disorders; ZymoGenetics reported positive data from a Phase III trial of its recombinant human thrombin product, and Medarex began a Phase II trial of two drugs for C. difficile associated diarrhea. The Centient Biotech 200™ dropped 66 points to close at 3716.6, a loss of 1.75%. More details...

Clinical ResultPhase 3Orphan DrugPhase 2

100 Deals associated with Opebacan

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D05265	-	-	DB06161

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Graft vs Host Disease	Phase 3	United States	XOMA (US) LLC	01 Feb 2007
Infectious Diseases	Phase 3	United States	The University of Texas Southwestern Medical Center	01 Apr 2006
Meningococcal Infections	Phase 3	-	XOMA Royalty Corp.	-
Radiation Injuries	Phase 3	-	XOMA Royalty Corp.	-
Surgical Wound Infection	Phase 3	-	XOMA Royalty Corp.	-
Wound Infection	Phase 3	-	XOMA Royalty Corp.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00462904 (CTgov)	Phase 2	Infectious Diseases	4	BPI	fvtayluiws(shedzducsd) = vjugrxnkqy fpqzvjhvhr (arugfylsph, cvtueqrzqx - deafyldbbq) View more	-	20 Nov 2019

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data